The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study.

CMAJ open Pub Date : 2019-10-01 DOI:10.9778/cmajo.20190068
N. Kronfli, C. Dussault, M. Klein, B. Lebouché, G. Sebastiani, J. Cox
{"title":"The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study.","authors":"N. Kronfli, C. Dussault, M. Klein, B. Lebouché, G. Sebastiani, J. Cox","doi":"10.9778/cmajo.20190068","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nHepatitis C virus (HCV) microelimination efforts must target people in prison; however, although some inmates may qualify for treatment in provincial prisons, it may not be routinely provided. Our aim was to characterize the cascade of HCV care in Quebec's largest provincial prison.\n\n\nMETHODS\nWe conducted a retrospective study of all HCV-related laboratory tests requested at the Établissement de détention de Montréal (men's prison with on-demand screening), between July 1, 2017, and June 30, 2018. We defined 8 HCV care cascade steps: 1) total sentenced inmates, 2) screened for HCV (via HCV antibody [HCV Ab]), 3) HCV Ab positive, 4) tested for HCV RNA, 5) HCV RNA positive, 6) linked to care, 7) HCV treatment initiated and 8) achieved sustained virologic response. We measured proportions of inmates at each step using denominator-numerator linkage. We also calculated the proportion screened among inmates with a sentence duration of at least 1 month, during which time screening should be feasible.\n\n\nRESULTS\nOf the 4931 sentenced inmates, 344 (7%) were screened for HCV, of whom 38 (11%) were HCV Ab positive. Thirty-five (92%) of the 38 received HCV RNA testing, which showed positivity in 16 (46%). Ten (62%) of the 16 inmates were linked to care; treatment was initiated in 3 (30%), 2 of whom (67%) achieved a sustained virologic response. Among inmates with a sentence duration of at least 1 month (n = 1972), the proportion screened increased to 17%.\n\n\nINTERPRETATION\nA small proportion (7%) of men at a Canadian provincial prison with on-demand HCV testing were screened, and rates of treatment initiation were low in the absence of formal HCV cure pathways. To eliminate HCV in this subpopulation, opt-out HCV testing should be considered.","PeriodicalId":93946,"journal":{"name":"CMAJ open","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.9778/cmajo.20190068","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CMAJ open","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.9778/cmajo.20190068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

Abstract

BACKGROUND Hepatitis C virus (HCV) microelimination efforts must target people in prison; however, although some inmates may qualify for treatment in provincial prisons, it may not be routinely provided. Our aim was to characterize the cascade of HCV care in Quebec's largest provincial prison. METHODS We conducted a retrospective study of all HCV-related laboratory tests requested at the Établissement de détention de Montréal (men's prison with on-demand screening), between July 1, 2017, and June 30, 2018. We defined 8 HCV care cascade steps: 1) total sentenced inmates, 2) screened for HCV (via HCV antibody [HCV Ab]), 3) HCV Ab positive, 4) tested for HCV RNA, 5) HCV RNA positive, 6) linked to care, 7) HCV treatment initiated and 8) achieved sustained virologic response. We measured proportions of inmates at each step using denominator-numerator linkage. We also calculated the proportion screened among inmates with a sentence duration of at least 1 month, during which time screening should be feasible. RESULTS Of the 4931 sentenced inmates, 344 (7%) were screened for HCV, of whom 38 (11%) were HCV Ab positive. Thirty-five (92%) of the 38 received HCV RNA testing, which showed positivity in 16 (46%). Ten (62%) of the 16 inmates were linked to care; treatment was initiated in 3 (30%), 2 of whom (67%) achieved a sustained virologic response. Among inmates with a sentence duration of at least 1 month (n = 1972), the proportion screened increased to 17%. INTERPRETATION A small proportion (7%) of men at a Canadian provincial prison with on-demand HCV testing were screened, and rates of treatment initiation were low in the absence of formal HCV cure pathways. To eliminate HCV in this subpopulation, opt-out HCV testing should be considered.
魁北克省监狱丙型肝炎病毒级联治疗:一项回顾性队列研究
背景丙型肝炎病毒(HCV)微清除工作必须针对监狱中的人;然而,尽管一些囚犯可能有资格在省级监狱接受治疗,但可能不会常规提供。我们的目的是描述魁北克省最大的省级监狱中丙型肝炎病毒护理的级联情况。方法在2017年7月1日至2018年6月30日期间,我们对蒙特利尔男子监狱要求的所有HCV相关实验室检测进行了回顾性研究。我们定义了8个HCV护理级联步骤:1)总判刑囚犯,2)HCV筛查(通过HCV抗体[HCV Ab]),3)HCV Ab阳性,4)HCV RNA检测,5)HCV RNA阳性,6)与护理相关,7)开始HCV治疗,8)获得持续的病毒学反应。我们使用分母-分子链接来测量每一步囚犯的比例。我们还计算了刑期至少为1个月的囚犯中接受筛查的比例,在此期间进行筛查应该是可行的。结果在4931名被判刑的囚犯中,344人(7%)接受了丙型肝炎病毒筛查,其中38人(11%)HCV抗体阳性。38人中有35人(92%)接受了HCV RNA检测,其中16人(46%)呈阳性。16名囚犯中有10名(62%)与护理有关;3例(30%)开始治疗,其中2例(67%)获得持续的病毒学应答。在刑期至少为1个月的囚犯中(n=1972),接受筛查的比例增加到17%。解释加拿大一所省级监狱中,一小部分(7%)按需进行丙型肝炎病毒检测的男性接受了筛查,在没有正式的丙型肝炎病毒治愈途径的情况下,开始治疗的比率很低。为了消除该亚群中的丙型肝炎病毒,应考虑选择不进行丙型肝炎病毒检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信